The expanding global demand for targeted medicine, coupled with the surging prevalence of cancer and other chronic diseases, is significantly fueling the expansion of the DNA methylation detection technology market. Advances in sequencing approaches, particularly those offering higher throughput and reduced cost, are additionaly contributing to mar